Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 11:24Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
-
Sep 11, 2026, 10:53A Patient-Centred Approach to Haemophilia B Care – EAHAD
-
Sep 11, 2026, 09:51Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
-
Sep 11, 2026, 09:35Yasir Khan: Travel Related Blood Clots – What Are the Chances?
-
Sep 11, 2026, 08:02Mud Alvi: Restarting Antithrombotic Therapy After Hemorrhagic Transformation of Ischemic Stroke
-
Sep 11, 2026, 08:01Chaza Alaji: Factor X From Inherited Deficiency to Acquired Deficiency in AL Amyloidosis
-
Sep 11, 2026, 08:01Mariusz Kowalewski: Risk Stratification of Surgical Ablation During Minimally Invasive Mitral Valve Surgery for AFib
-
Sep 11, 2026, 08:00Noor Gajraj: MTHFR Helps Turn Folate, Vitamin B9, Into The Form The Body Uses
-
Sep 11, 2026, 07:59Lisa Lacy: Living With Hereditary Antithrombin Deficiency and the Constant Threat of Clotting